HLH Clinical Trial
Official title:
Clinical Study on the Efficacy and Safety of Low-dose CD20 Monoclonal Antibody Injection in Preemptive Treatment of Lymphoproliferative Diseases After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With EBV-HLH/CAEBV
This is a clinical study on the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV
Purpose: To comprehend the efficacy and safety of low-dose CD20 monoclonal antibody injection in preemptive treatment of EBV positive lymphoproliferative diseases after allo-HSCT in patients with EBV-HLH and CAEBV Study subjects: PTLD patients undergoing allo-HSCT with CAEBV or EBV-HLH met the following conditions: (1) EBV-DNA (PBMC or plasma) > 1000 copies/ml in peripheral blood after transplantation; (2) no PTLD symptoms; (3) presence of aGVHD or clinicians believe that RI treatment is not suitable, or EBV-DNA persists > 1000 copies/ml after RI; (4) EBV infected lymphocytes; (4) B cell infection, or B cell copy number higher than other cell lines by 2 logs. Therapeutic regimen: CD20 monoclonal antibody injection 100 mg/m2 was intravenously infused once a week. It can be discontinued after EBV-DNA negative for 2 consecutive times. Total doseā¤ 4 applications per patient ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06048107 -
Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen
|
N/A | |
| Recruiting |
NCT04644016 -
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
|
Phase 2 | |
| Recruiting |
NCT05882175 -
Prospective Validation of the OHI Index
|
||
| Recruiting |
NCT04758650 -
Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis
|
Phase 2 | |
| Recruiting |
NCT05854225 -
Thiotepa Incorporating TBI/Cy Conditioning Regimen for EBV-HLH With Central Nervous System Involvement
|
N/A | |
| Completed |
NCT05320575 -
Zanubrutinib for HLH
|
Phase 3 | |
| Recruiting |
NCT05306080 -
Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
|
Early Phase 1 |